Accelerated clearance of a second injection of PEGylated liposomes in mice.
暂无分享,去创建一个
T. Ishida | H. Kiwada | Tatsuhiro Ishida | Hiroshi Kiwada | Kaori Masuda | Takako Ichikawa | Masako Ichihara | Kenji Irimura | M. Ichihara | K. Irimura | K. Masuda | Takako Ichikawa
[1] H. Harashima,et al. Kinetic modeling of liposome degradation in blood circulation , 1993, Biopharmaceutics & drug disposition.
[2] Kazuo Maruyama,et al. Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.
[3] H. Harashima,et al. Kinetic analysis of AUC-dependent saturable clearance of liposomes: Mathematical description of AUC dependency , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[4] D. Pode,et al. Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer , 2000, Anti-cancer drugs.
[5] F. Berr,et al. A phase II study of pegylated liposomal doxorubicin for treatment of advanced hepatocellular carcinoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] G. Hofstede,et al. Liposomal doxorubicin‐induced toxicity: Depletion and impairment of phagocytic activity of liver macrophages , 1995, International journal of cancer.
[7] B. Goins,et al. Repeat Injection Studies of Technetium-99M-Labeled Peg-Liposomes in the Same Animal , 1998 .
[8] T. Allen,et al. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. , 1991, Biochimica et biophysica acta.
[9] J. Hainsworth,et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] W. Oyen,et al. Accelerated blood clearance and altered biodistribution of repeated injections of sterically stabilized liposomes. , 2000, The Journal of pharmacology and experimental therapeutics.
[11] W. Oyen,et al. Factors affecting the accelerated blood clearance of polyethylene glycol-liposomes upon repeated injection. , 2001, The Journal of pharmacology and experimental therapeutics.
[12] T. Ishida,et al. Accelerated clearance of PEGylated liposomes in rats after repeated injections. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[13] G. R. Bartlett. Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.
[14] K. Avgoustakis,et al. Protein-induced CF release from liposomes in vitro and its correlation with the BLOOD/RES biodistribution of liposomes , 1998 .
[15] T M Allen,et al. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. , 1998, Cancer research.
[16] L J Liang,et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. T. ten Kate,et al. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. , 1995, The Journal of antimicrobial chemotherapy.
[18] G. Storm,et al. Sterically stabilized amphotericin B-liposomes : toxicity and biodistribution in mice , 1995 .
[19] H. Harashima,et al. Biodistribution of liposomes and C3 fragments associated with liposomes: evaluation of their relationship. , 2000, International journal of pharmaceutics.
[20] T. Allen. LIPOSOME TARGETING IN ANIMAL MODELS: PROBLEMS AND OPPORTUNITIES , 1997 .
[21] N. Brockmeyer,et al. Fatal hepatic failure with liposomal doxorubicin , 1993, The Lancet.